Market cap
₹219 Cr
Recently Viewed
Clear AllNSE: LYKALABS | BSE: 500259
₹60.38
₹1.00
(1.68%)
As on 29-Apr-2026IST
Market cap
₹219 Cr
Revenue (TTM)
₹134 Cr
P/E Ratio
--
P/B Ratio
2.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹-1 Cr
ROE
9.8 %
ROCE
10.1 %
Industry P/E
406.57
EV/EBITDA
23.5
Debt to Equity
0.4
Book Value
₹28.3
EPS
₹-0.2
Face value
10
Shares outstanding
35,690,000
CFO
₹213.42 Cr
EBITDA
₹233.78 Cr
Net Profit
₹-74.69 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lyka Labs
| -20.4 | 29.9 | -19.5 | -46.1 | -16.3 | 10.0 | -2.6 |
|
BSE Healthcare
| 2.8 | 5.2 | 8.2 | 4.9 | 24.7 | 13.9 | 11.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Lyka Labs
| -51.7 | 27.9 | -4.6 | -41.7 | 582.9 | 57.4 | -35.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lyka Labs
|
60.4 | 219.1 | 133.8 | -0.3 | -0.7 | -0.6 | -- | 2.2 |
| 181.3 | 2,842.5 | 2,796.8 | 118.8 | 8.1 | 2.3 | 23.9 | 0.4 | |
| 24.3 | 7.4 | 0.5 | 0.0 | 8.3 | -1.1 | -- | 1.9 | |
| 495.5 | 11,934.3 | 3,262.7 | 439.0 | 15.3 | 16 | 27.2 | 4.0 | |
| 187.8 | 8,499.1 | 2,803.3 | 361.8 | 15.5 | 14 | 23.6 | 3.0 | |
| 1,055.1 | 22,371.7 | 2,169.9 | 332.9 | 20.9 | 15.4 | 67.2 | 9.4 | |
| 4,788.4 | 11,052.7 | 935.0 | 257.9 | 34.3 | 78.9 | 42.9 | 24.5 | |
| 43.6 | 641.2 | 0.0 | 1.6 | -- | -0.5 | 398.5 | 23.8 | |
| 27.8 | 61.8 | 51.4 | 4.5 | 22.0 | 5.2 | 13.7 | 0.6 |
No Review & Analysis are available.
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical... steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, anti-fungal and bacterial, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports its products. The company was incorporated in 1976 and is based in Mumbai, India. Read more
Incorporated
1976
Chairman
Babulal Jain
Managing Director
Kunal N Gandhi
Headquarters
Ankleshwar, Gujarat
Website
Looking for more details about Lyka Labs Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsUpdate On The Scheme Of Amalgamation
09-Apr-2026Clarification On Price Movement
09-Apr-2026Clarification Sought from Lyka Labs Ltd
08-Apr-2026Update On The Scheme Of Amalgamation
20-Feb-2026No News & Announcements are available.
The share price of Lyka Labs Ltd is ₹60.38 (NSE) and ₹61.39 (BSE) as of 29-Apr-2026 IST. Lyka Labs Ltd has given a return of -16.32% in the last 3 years.
Since, TTM earnings of Lyka Labs Ltd is negative, P/E ratio is not available.
The P/B ratio of Lyka Labs Ltd is 2.17 times as on 29-Apr-2026, a 15 premium to its peers’ median range of 1.88 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
44.97
|
3.48
|
|
2024
|
0.00
|
5.93
|
|
2023
|
0.00
|
11.47
|
|
2022
|
9.98
|
29.17
|
|
2021
|
0.00
|
-2.89
|
The 52-week high and low of Lyka Labs Ltd are Rs 128.78 and Rs 44.10 as of 29-Apr-2026.
Lyka Labs Ltd has a market capitalisation of ₹ 219 Cr as on 29-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Lyka Labs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.